SCHEMBL3040201

SCHEMBL3040201

CCCCCCCCCCCC(=O)OCC(O)CN(CCCCC(N)C(=O)OCC)CC(O)COC(=O)CCCCCCCCCCC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.51
▸ KDM4E B2RXH2 1/20 0.51
▸ DUSP3 P51452 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ P2RY10 O00398 6/20 0.47
▸ GPR174 Q9BXC1 6/20 0.47
▸ GPR34 Q9UPC5 5/20 0.47
▸ MAPT P10636 1/20 0.47
▸ ENPP2 Q13822 4/20 0.46
▸ LPAR6 P43657 1/20 0.46
▸ LPAR1 Q92633 1/20 0.46
▸ LPAR4 Q99677 1/20 0.46
▸ LPAR5 Q9H1C0 1/20 0.46
▸ LPAR2 Q9HBW0 1/20 0.46
▸ LPAR3 Q9UBY5 1/20 0.46
▸ DGKA P23743 1/20 0.45
▸ TRPV1 Q8NER1 1/20 0.44
▸ NOD1 Q9Y239 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3021227 1.00 LMNA (0.51) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL3042150 1.00 LMNA (0.51) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL3035767 0.96 KDM4E (0.56) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL3035056 0.96 KDM4E (0.56) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL3038002 0.93 LMNA (0.54) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL3040870 0.93 LMNA (0.54) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL3032477 0.91 P2RY10 (0.52) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL3040154 0.91 P2RY10 (0.52) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL3027339 0.91 P2RY10 (0.52) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL3027166 0.88 ALDH1A1 (0.59) LMNAENPP2LPAR1LPAR2LPAR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100202998-A1 USE OF AT LEAST ONE LYSINE-DERIVED COMPOUND FOR THE CONDITIONING OF KERATINOUS FIBERS, COSMETIC COMPOSITION COMPRISING IT AND METHOD FOR CONDITIONING THE FIBERS L'OREAL S.A. (FR) 2010-08-12 — — US claimed
US-20100202998-A1 USE OF AT LEAST ONE LYSINE-DERIVED COMPOUND FOR THE CONDITIONING OF KERATINOUS FIBERS, COSMETIC COMPOSITION COMPRISING IT AND METHOD FOR CONDITIONING THE FIBERS L'OREAL S.A. (FR) 2010-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100202998-A1 USE OF AT LEAST ONE LYSINE-DERIVED COMPOUND FOR THE CONDITIONING OF KERATINOUS FIBERS, COSMETIC COMPOSITION COMPRISING IT AND METHOD FOR CONDITIONING THE FIBERS KRT18, DSG1, PLOD3 LMNA 520/4885KDM4E 194/4885DUSP3 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback